Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 3
1998 2
1999 5
2000 6
2001 2
2002 3
2003 2
2004 3
2005 6
2006 3
2007 5
2008 7
2009 10
2010 13
2011 22
2012 21
2013 28
2014 36
2015 31
2016 21
2017 27
2018 29
2019 32
2020 25
2021 17
2022 23
2023 19
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Results by year

Filters applied: . Clear all
Page 1
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR. Saad F, et al. Among authors: tombal b. Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.03.036. Online ahead of print. Eur Urol. 2024. PMID: 38644146 Free article.
Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial.
Achard V, Fournier B, D'Haese D, Krzystyniak J, Tombal B, Roupret M, Sargos P, Dirix P. Achard V, et al. Among authors: tombal b. Eur Urol Oncol. 2024 Mar 30:S2588-9311(24)00084-1. doi: 10.1016/j.euo.2024.03.008. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38556413
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
Kwak L, Ravi P, Armstrong JG, Beckendorf V, Chin JL, D'Amico AV, Dearnaley DP, Di Stasi SM, Gillessen S, Lukka H, Mottet N, Pommier P, Seiferheld W, Sydes MR, Tombal B, Zapatero A, Regan MM, Xie W, Sweeney CJ. Kwak L, et al. Among authors: tombal b. J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762. Online ahead of print. J Clin Oncol. 2024. PMID: 38471051
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, Sartor O. Higano CS, et al. Among authors: tombal b. Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221. Online ahead of print. Cancer. 2024. PMID: 38340349
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y. Tombal BF, et al. Eur Urol Oncol. 2024 Jan 24:S2588-9311(24)00034-8. doi: 10.1016/j.euo.2024.01.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38272747 Free article.
336 results